Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C. Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]
Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/ emotional, and cognitive outcomes in children. Rodrigue JR, Balistreri W, Haber B, et al. Hepatology. 2011 Feb 23. doi: 10.1002/hep.24248. [Epub ahead of print]
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Durante-Mangoni E, Iossa D, Pinto D, et al. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]
Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcome of Patients with Advanced Chronic Hepatitis C. Lambrecht RW, Sterling RK, Naishadham D, et al. Gastroenterology. 2011 Feb 15. [Epub ahead of print]
Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. Itoh Y, Nishimura T, Hashimoto H, et al. Hepatol Res. 2011 Feb;41(2):126-32. doi: 10.1111/j.1872-034X.2010.00750.x.
Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Aoki YH, Ohkoshi S, Yamagiwa S, et al. Hepatol Res. 2011 Feb;41(2):118-25. doi: 10.1111/j.1872-034X.2010.00749.x.
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, et al. Ther Drug Monit. 2011 Feb;33(1):40-4.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. Forestier N, Larrey D, Guyader D, et al. J Hepatol. 2011 Feb 10. [Epub ahead of print]
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Martin NK, Vickerman P, Foster GR, et al. J Hepatol. 2011 Feb 11. [Epub ahead of print]
Association of caffeine intake and histological features of chronic hepatitis C. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. J Hepatol. 2011 Feb 10. [Epub ahead of print]
Factors influencing the response of interferon therapy in chronic hepatitis C patients.
Ahmed WU, Arif A, Qureshi H, et al. J Coll Physicians Surg Pak. 2011 Feb;21(2):69-73.
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Doehring A, Hofmann WP, Schlecker C, et al. Pharmacogenet Genomics. 2011 Feb 19. [Epub ahead of print]
Polymorphisms of Hepatitis C Virus Non-Structural Protein 5A and Core Protein and Clinical Outcome of Pegylated-Interferon/Ribavirin Combination Therapy. El-Shamy A, Kim SR, Ide YH, et al. Intervirology. 2011 Feb 4. [Epub ahead of print]
Novel mutations in a tissue-culture adapted HCV strain improve infectious virus stability and markedly enhance infection kinetics. Pokrovskii MV, Bush CO, Beran RK, et al. J Virol. 2011 Feb 2. [Epub ahead of print]
Effect of suppressor of cytokine signaling on hepcidin production in hepatitis C virus replicon cells. Miyachi H, Kobayashi Y, Relja B, Fujita N, Iwasa M, Gabazza EC, Takei Y. Hepatol Res. 2011 Feb 23. doi: 10.1111/j.1872-034X.2011.00777.x. [Epub ahead of print]
Aberrant transcription and post-transcriptional processing of hepatitis C virus non-structural genes in transgenic mice. Desai MM, Tumurbataar B, Zhang Y, Chan LN, Sun J, Chan TS. Transgenic Res. 2011 Feb 24. [Epub ahead of print]
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly. Popescu CI, Callens N, Trinel D, et al. PLoS Pathog. 2011 Feb 10;7(2):e1001278.
Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Yunihastuti E, Lee S, Gani RA, et al. Clin Immunol. 2011 Feb 3. [Epub ahead of print]
Incidence and Predictors of Acute Kidney Injury in an Urban Cohort of Subjects with HIV and Hepatitis C Virus Coinfection. Garg S, Hoenig M, Edwards EM, et al. IDS Patient Care STDS. 2011 Feb 10. [Epub ahead of print]
Controlled HIV Viral Replication, Not Liver Disease Severity Associated with Low Bone Mineral Density in HIV/HCV Co-Infection. El-Maouche D, Mehta SH, Sutcliffe C, et al. J Hepatol. 2011 Feb 18. [Epub ahead of print]
Acute hepatitis C infection in HIV-positive patients. Vogel M, Boesecke C, Rockstroh JK. Curr Opin Infect Dis. 2011 Feb;24(1):1-6.
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
de Araujo ES, Dahari H, Cotler SJ, et al. J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):95-9.
Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study. Gamage DG, Read TR, Bradshaw CS, et al. BMC Infect Dis. 2011 Feb 3;11(1):39.
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Terrier B, Carrat F, Geri G, et al. J Hepatol. 2011 Feb 17. [Epub ahead of print]
Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. Thorpe J, Saeed S, Moodie EE, et al. AIDS. 2011 Feb 16. [Epub ahead of print]
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. Abe H, Hayes CN, Ochi H, et al. J Hepatol. 2011 Feb 4. [Epub ahead of print]
Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. Devitt EJ, Power KA, Lawless MW, et al. Eur J Gastroenterol Hepatol. 2011 Feb;23(2):177-83.
Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006.
Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]
Liver fibrosis in patients with chronic hepatitis C: noninvasive diagnosis by means of real-time tissue elastography--establishment of the method for measurement. Koizumi Y, Hirooka M, Kisaka Y, et al. Radiology. 2011 Feb;258(2):610-7.
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use.
Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]
Guidance for clinical trials for children and adolescents with chronic hepatitis C.
Wirth S, Kelly D, Sokal E, et al. J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):233-7.
A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma. Kozyreva ON, Chi D, Clark JW, et al. Oncologist. 2011 Feb 24. [Epub ahead of print]
Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. Takahashi H, Mizuta T, Eguchi Y, et al. J Gastroenterol. 2011 Feb 18. [Epub ahead of print]
High Levels of HCV core+1 Antibodies in HCV Patients with Hepatocellular Carcinoma.
Dalagiorgou G, Vassilaki N, Foka P, et al. J Gen Virol. 2011 Feb 9. [Epub ahead of print]
Role of MMP14 Gene Polymorphisms in Susceptibility and Pathological Development to Hepatocellular Carcinoma. Chen TY, Li YC, Liu YF, et al. Ann Surg Oncol. 2011 Feb 5. [Epub ahead of print]
Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? Lok AS. J Gastroenterol Hepatol. 2011 Feb;26(2):221-7. doi: 10.1111/j.1440-1746.2010.06576.x.